Immunogenic Compositions to Treat and Prevent Microbial Infections
The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition. The invention also relates to antibodies to composite antigens of the invention and to methods of administering vaccines comprising antigens or vaccines of antibodies for treating and/or preventing an infection.
1 . An immunogenic peptide comprised of one or more epitopes specific to a corona virus polymerase along a single sequence that does not contain an epitope specific to a coronavirus spike protein, a coronavirus membrane protein, a coronavirus envelope protein, and/or a coronavirus structural protein.
2 . The peptide of claim 1 , which comprises only the one or more epitopes specific to coronavirus polymerase.
3 . The peptide of claim 1 , which further comprises one or more epitopes specific to viruses other than coronavirus.
4 . The peptide of claim 1 , which further comprises one or more epitopes specific to a bacteria.
5 . The peptide of claim 1 , wherein the peptide comprises a sequence containing one or more of SEQ ID NOs 35-48 and 116-128.
6 . The peptide of claim 1 , which comprises at least one T cell stimulating epitope.
7 . The peptide of claim 6 , wherein the T cell stimulating epitope is at the N-terminus of the peptide.
8 . The peptide of claim 6 , wherein the T cell stimulating epitope is at the C-terminus of the peptide.
9 . The peptide of claim 6 , wherein the T cell stimulating epitope is at an internal region of the peptide.
10 . A composition comprising the peptide of claim 1 and a pharmaceutically acceptable diluent, excipient, or carrier.
11 . The composition of claim 1 , further comprising an adjuvant.
12 . The composition of claim 11 , wherein the adjuvant is selected from the group consisting of Freund's, a liposome, saponin, lipid A, squalene, and derivatives and combinations thereof.
13 . A vaccine comprising the peptide of claim 1 .
14 . An immunogenic peptide containing a plurality of microbial epitopes, wherein the plurality comprises the peptide of claim 1 , one or more epitopes of peptidoglycan of a Mycobacterium and one or more epitopes of a neuraminidase protein of an influenza virus, wherein the plurality is contained in a contiguous peptide sequence.
15 . An immunogenic peptide containing a plurality of microbial epitopes, wherein the plurality comprises the peptide of claim 1 , one or more epitopes of a heat shock protein of a Mycobacterium and one or more epitopes of a matrix protein of an influenza virus, wherein the plurality is contained in a contiguous peptide sequence.
16 . A collection of antibodies that are specifically reactive to the one or more epitopes of the peptide of claim 1 .
17 . A monoclonal antibody that is specifically reactive to the one or more epitopes of the peptide of claim 1 .
18 . The monoclonal antibody of claim 17 , which is human or humanized.
19 . The monoclonal antibody of claim 17 , which is an IgG or an IgM antibody.
20 . The monoclonal antibody of claim 17 , which has an extended half-life.
21 . The monoclonal antibody of claim 20 , which contains a mutation in an Fc region.
22 . A hybridoma that expresses the monoclonal antibody of claim 17 .
23 . A method for treating or preventing a coronavirus infection comprising administering the peptide of claim 1 to a subject.
24 . A method for treating or preventing a coronavirus infection comprising administering the collection of antibodies of claim 16 to a subject.
25 . A method for treating or preventing a coronavirus infection comprising administering the monoclonal antibody of claim 17 to a subject.